Physician profile

Amy O Daniel

Family · Tupelo, MS

NPI 1669879003

$328.02

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$95.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $95.51 2021-2024
Novo Nordisk INC $50.62 2021-2022
Glaxosmithkline, LLC. $42.23 2022-2023 Arexvy, Shingrix
Boehringer Ingelheim Pharmaceuticals, INC. $33.57 2021-2023 Ofev
Shield Therapeutics INC $30.41 2024
Amgen INC. $26.49 2022-2024 Otezla, Repatha
Genentech USA, INC. $23.61 2021
Lilly USA, LLC $14.34 2022
Takeda Pharmaceuticals U.S.A., INC. $11.24 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amy O Daniel

$328.02

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/11235803/amy-o-daniel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.